Clinical Trial

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Study acronym: MAPKeeper 301
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Protocol Amendment History 7 changes
notable Trial sites expanded: 25 -> 30 locations 2026-07-28
notable Trial sites expanded: 19 -> 22 locations 2026-07-07
notable Trial sites expanded: 16 -> 19 locations 2026-06-23
notable Trial sites expanded: 13 -> 17 locations 2026-06-13
notable Trial sites expanded: 10 -> 13 locations 2026-06-09
notable Trial sites expanded: 6 -> 10 locations 2026-06-05
notable Trial sites expanded: 3 -> 6 locations 2026-05-07
Trial Details
NCT Number NCT07562152
Lead Sponsor Immuneering Corporation
Conditions Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma
Enrollment 510 participants
Start Date 2026-06-05
Primary Completion 2028-06 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-14